Key result
Brain-acting ARBs and ACE inhibitors show potential clinical benefits for cognition, Alzheimer's disease, and pain.
Why the study?
Continuous efforts have explored the endogenous brain renin-angiotensin system and its pleiotropic properties, motivating a summary of recent advances in its pathophysiology and treatment in central nervous system disorders.
This review highlights the role of the brain renin-angiotensin system and the potential of ARBs and ACE inhibitors in treating central nervous system disorders such as Alzheimer's disease and pain.
No takes yet. Share an insight, caveat, or question.
May support exploratory trials of ARBs and ACE inhibitors in cognition and pain; leaves open confirmation in dedicated RCTs before any practice change.
Aswar et al. (2021) conducted a review in Central nervous system-related disorders. ARBs and ACE inhibitors was evaluated. Drugs acting on the brain renin-angiotensin system, predominantly ARBs and ACE inhibitors, show potential effectiveness in clinical trials for cognition, memory, Alzheimer's disease, and pain.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: